Values as of: 2024-11-04
ETF | Health |
Last Closing
USD 29.24Change
+0.45 (+1.56)%Market Cap
USD 0.01BVolume
473.00Analyst Target
N/AVerdict
Verdict
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Company Website : http://www.virtus.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| XLV | Health Care Select Sector SPDR.. |
-0.97 (-0.66%) |
USD 40.26B |
| FHLC | Fidelity® MSCI Health Care In.. |
-0.43 (-0.61%) |
USD 2.86B |
| FXH | First Trust Health Care AlphaD.. |
-0.16 (-0.15%) |
USD 1.18B |
| XHE | SPDR® S&P Health Care Equipme.. |
+1.18 (+1.33%) |
USD 0.21B |
| IDNA | iShares Genomics Immunology an.. |
+0.06 (+0.24%) |
USD 0.14B |
| SBIO | ALPS Medical Breakthroughs ETF |
+0.28 (+0.73%) |
USD 0.12B |
| XHS | SPDR® S&P Health Care Service.. |
-0.35 (-0.37%) |
USD 0.08B |
| HTEC | Robo Global® Healthcare Techn.. |
+0.35 (+1.23%) |
USD 0.05B |
| BBP | Virtus LifeSci Biotech Product.. |
-0.26 (-0.40%) |
USD 0.02B |
| IHF | iShares U.S. Healthcare Provid.. |
-0.13 (-0.25%) |
N/A |
N/A
| Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 19.58% | 100% | F | 78% | C+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 19.58% | 100% | F | 78% | C+ | ||
| Trailing 12 Months | |||||||
| Capital Gain | 55.58% | 100% | F | 87% | B+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 55.58% | 100% | F | 87% | B+ | ||
| Trailing 5 Years | |||||||
| Capital Gain | 7.50% | 52% | F | 57% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 7.50% | 52% | F | 57% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -1.64% | 10% | F | 27% | F | ||
| Dividend Return | -1.57% | 10% | F | 16% | F | ||
| Total Return | 0.07% | 21% | F | 3% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 35.73% | 5% | F | 28% | F | ||
| Risk Adjusted Return | -4.40% | 10% | F | 20% | F | ||
| Market Capitalization | 0.01B | 10% | F | 8% | B- | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
